Business Wire

CIRIUM

18.5.2022 13:32:08 CEST | Business Wire | Press release

Share
Cirium Partners With 3Victors to Offer the Most Dynamic Travel Demand Forecasting

Cirium , the aviation analytics company, and travel data analytics firm, 3Victors today announced a reseller partnership to enable Cirium to bring together flight schedules and passenger traffic data with online search data to interpret, understand and forecast passenger demand for airports and DMOs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005656/en/

“Cirium and 3Victors share the mission to revolutionize the way the travel industry forecasts future demand,” said Kim Gesch, VP Airline Planning at Cirium. “Airlines and airports worldwide have long used the Diio by Cirium suite of products for network and traffic analysis. We have invested in the products and have enhanced the quality of our schedules, traffic, and fares data to ensure we maintain our leading position in the market.”

Chris Zando, CEO at 3Victors said: “Both 3Victors and Cirium are focused on high quality data science to bring real-time insights to commercial decision-making for the industry. The combination of both our capabilities provides the most dynamic forecasting in the market and at a time when it is most needed.”

Travel demand models have traditionally been built by comparing current bookings for flights against historical trends. Ticket prices were raised and lowered based on indicators from these models to ensure a flight was booked at optimum fare levels. Post-pandemic, changes to traveler booking behavior means past booking patterns may no longer be reliable as a guide to future demand.

Cirium and 3Victors will join forces to offer the most complete solution for analyzing future traffic, monitoring trends across time and detecting emerging opportunities. The offering will include the Diio by Cirium flight schedules, traffic and fares data alongside 3Victors DemandView search data, providing the most accurate forecast as possible.

This is particularly important for airports seeking better insights to retain and gain air service or DMOs wanting to optimize their marketing campaigns and traveler conversion rates.

3Victors’ search data is captured from more than half a million global touchpoints, including when a prospective traveler visits traditional or online travel agency, meta search, or travel search engine: or searches for flights. The most advanced data science is applied to interpret the traveler behavior, which provides a clear demand signal for flight bookings.

An example using 3Victors data shows that on a recent date there were large spikes in domestic demand originating in the UK and US, along with output showing year-over-year variation. If historical trends alone were used to forecast travel demand, the spikes in travel being seen in 2022 to date would not have been forecast.

Said Cirium’s Gesch: “Pairing Cirium’s capabilities with 3Victors’ contemporary travel demand insights means we can offer clients worldwide the most advanced solution to determine accurate traveler intent, monitor passenger trends, and identify correlations between what travelers are searching and actually booking.”

Ends

About Cirium

Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com

About 3Victors

3Victors has built the industry’s first travel data analytics as a service platform in the Cloud. 3V’s proprietary 360° view of the travel landscape is the nexus between data volume, variety and velocity. 3V delivers market-leading data coverage and real-time analytics and insights, empowering companies with actionable intelligence.

For further information please follow 3Victors on LinkedIn or visit https://www.3victors.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release

Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa

EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release

EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye